Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical efficacy and safety of AM in the treatment of advanced progressed epidermal growth factor receptor tyrosine kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ping, Zhang, Liqin, Zhang, Xianru, Yu, Jiawen, Sun, Jun, Jiang, Qi-an, Zha, Mingbao, Nesterova, Anastasia P., Cao, Hongbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768876/
https://www.ncbi.nlm.nih.gov/pubmed/31570733
http://dx.doi.org/10.1038/s41598-019-50350-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768876/
https://www.ncbi.nlm.nih.gov/pubmed/31570733
http://dx.doi.org/10.1038/s41598-019-50350-6

Ejemplares similares